Page 108 - GTM-3-4

Global Translational Medicine Prediction of in-stent restenosis

system in diabetic patients. A survey of controlled studies. 2023;18:e1328-e1338.
Haemostasis. 1986;16(6):386-416.
doi: 10.4244/EIJ-D-22-00860
doi: 10.1159/000215317
31. Takebayashi H, Mintz GS, Carlier SG, et al. Nonuniform strut
22. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity distribution correlates with more neointimal hyperplasia
and insertion/dele-tion polymorphism of angiotensin after sirolimus-eluting stent implantation. Circulation.
I-converting enzyme: A major risk factor and a marker of risk 2004;110(22):3430-3434.
for coronary stent restenosis. Circulation. 1998;97(2):147-154. doi: 10.1161/01.CIR.0000148371.53174.05
doi: 10.1161/01.cir.97.2.14741 32. Guo X, Shen R, Yan S, Su Y, Ma L. Triglyceride-glucose
23. Vogiatzi K, Apostolakis S, Voudris V, Thomopoulou S, index for predicting repeat revascularization and in-stent
Kochiadakis GE, Spandidos DA. Interleukin 8 gene restenosis in patients with chronic coronary syndrome
polymorphisms and susceptibility to rest-enosis after undergoing percutaneous coronary intervention. Cardiovasc
percutaneous coronary intervention. J Thromb Thrombolysis. Diabetol. 2023;22(1):43.
2010;29(1):134-140. doi: 10.1186/s12933-023-01779-7

doi: 10.1007/s11239-009-0338-y42 33. Cabrera-Rego JO, Escobar-Torres RA, Parra-Jiménez JD,
24. Richardson A, Kaye SB. Drug resistance in ovarian cancer: Valiente-Mustelier J. Epicardial fat thickness correlates with
the emerging im-portance of gene transcription and spatio- coronary in-stent restenosis in patients with acute myocardial
temporal regulation of resistance. Drug Resist Updates. infarction. Clin Investig Arterioscler. 2019;31(2):49-55.
2005;8(5):311-321. doi: 10.1016/j.arteri.2018.11.002
doi: 10.1016/j.drup.2005.09.001 34. Zhang W, Zhang M, Tian J, Zhang M, Zhou Y, Song X.
25. Iijima R, Byrne RA, Ndrepepa G, et al. Pre-procedural Drug-coated balloon-only strategy for de novo coronary
C-reactive protein levels and clinical out-comes after artery disease: A meta-analysis of randomized clinical trials.
percutaneous coronary interventions with and without Cardiovasc Ther. 2023;8:3121601.
ABCIX-IMAB: Pooled analysis of four ISAR trials. Heart. doi: 10.1155/2023/3121601
2009;95(2):107-112.
35. Kokkinidis DG, Waldo SW, Armstrong EJ. Treatment of
doi: 10.1136/hrt.2008.15363547 coronary artery in-stent restenosis. Expert Rev Cardiovasc
26. Dibra A, Mehilli J, Braun S, et al. Inflammatory response Ther. 2017;15(3):191-202.
after intervention assessed by serial C-reactive protein doi: 10.1080/14779072.2017.1284588
measurements correlates with rest-enosis in patients treated
with coronary stenting. Am Heart J. 2005;150(2):344-350. 36. Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-
eluting stent versus drug-coated balloon in non-ST-elevation
doi: 10.1016/j.ahj.2004.09.030 myocardial infarction: the randomised PEPCAD NSTEMI
27. Moreno PR, Bernardi VH, López-Cuéllar J, et al. trial. Eurointervention. 2020;15(17):1527-1533.
Macrophage infiltration predicts rest-enosis after coronary doi: 10.4244/EIJ-D-19-00723
intervention in patients with unstable angina. Circulation.
1996;94(12):3098-3102. 37. Zhang J, Zhang Q, Zhao K, Bian YJ, Liu Y, Xue YT.
Risk factors for in-stent restenosis after coronary stent
doi: 10.1161/01.cir.94.12.3098 implantation in patients with coronary artery disease: A
28. Katsaros KM, Wiesbauer F, Speidl WS, et al. High soluble retrospective observational study. Medicine (Baltimore).
Fas and soluble Fas ligand serum levels before stent 2022;101(47):e31707.
implantation are protective against restenosis. Thromb doi: 10.1097/MD.0000000000031707
Haemostasis. 2011;105(5):883-891.
38. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated
doi: 10.1160/TH10-09-0566 balloon angioplasty vs. drug-eluting stenting for the
29. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of treatment of coronary in-stent restenosis: A comprehensive,
stent underexpansion to recurrence after sirolimus-eluting collaborative, individual patient data meta-analysis of 10
stent implantation for in-stent restenosis. Circulation. randomized clinical trials (DAEDALUS study). Eur Heart J.
2004;109(9):1085-1088. 2020;41:3715-3728.
doi: 10.1093/eurheartj/ehz594
doi: 10.1161/01.CIR.0000121327.67756.19
39. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/
30. Coughlan JJ, Aytekin A, Lahu S, et al. Derivation
and validation of the ISAR score to predict the risk EACTS Guidelines on myocardial revascularization.
of repeat percutaneous coronary interventions for EuroIntervention. 2019;14:1435-1534.
recurrent drug-eluting stent restenosis. EuroIntervention. doi: 10.4244/EIJY19M01_01

Volume 3 Issue 4 (2024) 10 doi: 10.36922/gtm.4957